Article
Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Clinical therapeutics - 1 Apr 2008
Kuypers Dirk R J, de Jonge Hylke, Naesens Maarten, de Loor Henriette, Halewijck Evelyne, Dekens Marc, Vanrenterghem Yves
Abstract excerpt
BACKGROUND: Two recent randomized clinical trials--Fixed Dose Versus Concentration Controlled and the Apomygre--evaluating the benefit of therapeutic drug monitoring of mycophenolate mofetil (MMF) in renal allograft recipients reported conflicting results. In both studies, target mycophenolic acid (MPA) AUC(0-12 h) ranges (ie, values used to guide MMF dosing) were derived from a previous study establishing target...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.